Cardinal Health Deep Value Investment Analysis

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it growing a bigger slice of an existing pie, or creating an entirely new market?5/10

  A

  Conclusion: the ceiling is high, but it belongs to "growing a bigger slice of an already-enormous existing pie," not creating an entirely new market. Cardinal Health's arena is U.S. pharmaceutical and medical-supply distribution — an already-existing, trillion-dollar-scale, long-term low-and-steady-growth mature market; its growth doesn't come from opening up uncharted territory, but from taking share within existing demand and extending into higher-value-add specialty/home-care segments.

  First, look at how big the pie is and how fast it's growing. U.S. prescription-drug spending is projected to grow 4.5%–7.5% annually on a net-price basis through 2030 (6%–9% on a list-price basis), with net spending increasing by about $200 billion from 2025 to 2030; meanwhile more than 90% of U.S. prescription drugs are distributed through wholesalers, with Cencora, Cardinal, and McKesson together accounting for more than 90% of pharmaceutical wholesale distribution. In other words, CAH already sits inside an extremely large stock market that is expanding steadily but only at a mid-single-digit rate — that's a textbook feature of "growing an existing pie," not the "exponential new market" Baillie Gifford loves most. The report's own characterization here is honest: it calls CAH a "healthcare supply-chain utility" — demand is stable but not exciting.

  What can genuinely raise the ceiling are the two incremental growth curves CAH is actively climbing, though these too are still splitting an already-existing pool of healthcare spending — just capturing a thicker-margin slice of it:

  • Specialty pharmacy and physician-management services (MSO/specialty). This is CAH's biggest current bet, and it is genuinely redefining its growth ceiling. Management's FY2026 guidance points to specialty revenue exceeding $50 billion in FY2026, a roughly 16% three-year compound growth rate, with The Specialty Alliance already covering about 3,000 specialty physicians across 32 states. Buy-and-bill oncology, urology, and rheumatology drugs carry far higher unit value than ordinary distribution — a thicker-margin slice of the same pool of healthcare spending.

  • Home care, radiopharmaceuticals/precision health, OptiFreight logistics, and other growth segments. The report lists these as value-add directions beyond traditional distribution, again with the same logic of lengthening the service chain along an existing patient and hospital network.

  But a high ceiling doesn't mean CAH can capture the whole pie's profit — two hard constraints need to be honestly flagged. First, blockbuster categories like GLP-1s meaningfully boosted revenue, but the company explicitly discloses that GLP-1 sales did not meaningfully contribute to segment profit — showing that "the market getting bigger" doesn't necessarily mean "CAH's profit pool getting bigger"; the volume ceiling and the profit ceiling are two different things. Second, the specialty track is the same pie all three giants are eyeing: the industry has collectively spent over $16 billion acquiring various MSOs in recent years, and CAH is competing with McKesson and Cencora for the same pool of physician networks, not staking out an uncontested blue ocean.

  So, measured by Baillie Gifford's yardstick: this is an extremely large but only moderately growing mature market, from which CAH can only extract a thin slice of profit. Its "ceiling" is more about "whether it can move its position within the existing pie from the thinnest distribution slice to the thicker specialty/home-care slice," rather than "whether it can conjure a new world out of nothing." That makes it a good defensive business, but not a great growth stock in the Baillie Gifford sense of "a market that is itself expanding exponentially."

  Jun 10, 2026
• QCan its revenue at least double over the next five years? Is growth driven mainly by volume, price, or new businesses?3/10

  A

  Conclusion: doubling revenue over the next five years (about 15% annualized) is almost impossible to achieve organically; the recent high growth rate is an "inflated" figure driven by acquisition consolidation plus specialty volume ramp-up, while the sustainable organic center of gravity is only low single digits. Doubling is simply too high a bar for an oligopoly distributor, and CAH is no exception.

  First, break apart the recent numbers that "look aggressive." CAH's FY2026 nine-month revenue was about $190.6 billion, up 17% year over year, with the Pharmaceutical and Specialty Solutions segment revenue at about $176 billion, up 18%; FY2026 Q3 alone had revenue of about $60.9 billion, up 11% year over year. At first glance this growth rate doesn't seem far from "doubling in five years" — but this is exactly where misjudgment happens most easily, and it needs to be broken down into three layers:

  • The price factor (the largest, but low profit content). A large chunk of revenue comes from net drug-price increases and volume growth in high-priced blockbusters like GLP-1s. The company explicitly states that GLP-1 sales boosted the Pharma segment and consolidated revenue but did not meaningfully contribute to segment profit. This "pass-through" style revenue growth is the norm for a distribution business — large in dollar terms, but essentially passing along the drugmaker's price, leaving CAH an extremely thin margin.

  • The volume factor (stable but modest). Underlying prescription volume is stable, but only growing modestly: at the industry level, U.S. net prescription-drug spending is projected to grow at about 4.5%–7.5% annually through 2030. That means "volume" alone can't carry a doubling.

  • The new-business/acquisition factor (the real amplifier behind current growth). The key reason FY2026 nine-month growth reached +17% is the consolidation of specialty MSOs: FY2025 saw the completion of GI Alliance (about $2.8 billion, buying 73% initially), ION (about $1.1 billion), and ADS (about $1.1 billion), and in FY2026 Solaris Health (about $1.9 billion, the country's largest urology MSO with 750+ physicians) was folded into The Specialty Alliance at about a 75% stake. In other words, a sizable portion of that 17% is "bought revenue" being consolidated for the first year, not same-store organic growth.

  Once you break apart these three layers, the answer to "can it double in five years" becomes clear. Doubling requires about 15% annualized growth, and:

  1. The base is already enormous. FY2025 revenue already reached $222.6 billion; compounding 15% for five straight years on a $200 billion-plus base would mean recreating an entire second CAH within five years — unrealistic for a thin-margin distributor.
  2. Organic growth is structurally low. Strip out acquisition consolidation and drug-price inflation, and core distribution's organic growth simply tracks prescription volume at low single digits; the report itself positions CAH as a defensive stock that "accepts low-to-mid growth." The specialty segment is fast (management guides specialty revenue past $50 billion in FY2026, about 16% three-year compound growth), but it's still only a bit over a fifth of the total — not enough to pull the whole company toward doubling.
  3. Large-customer volatility is a downside risk. The report documents the OptumRx contract expiration — that customer once contributed 17% of FY2024 consolidated revenue and directly weighed on FY2025 — the same kind of large contract that can inflate revenue can also cut it; growth isn't one-directional.

  The honest conclusion: if it keeps making acquisitions, "substantial" nominal revenue growth over the next five years isn't impossible, but that would be buying scale with shareholder money and debt — not the product-driven or market-expansion-driven organic doubling that Baillie Gifford values. The true organic revenue center of gravity is only low single digits, and even with specialty ramp-up layered on top, hitting "doubling in five years" is very unlikely. Growth is driven mainly by "price (low profit content) plus acquisition consolidation," with volume as the modest baseline — and the quality of these three drivers is precisely why it doesn't earn a place in the Baillie Gifford growth narrative.

  Jun 10, 2026
• QFive years from now, what will take the baton as the next growth engine? Does this "second curve" exist today?4/10

  A

  Conclusion: the second curve already exists today, and it's already ramping up with real money behind it — it's the cluster of specialty pharmacy + medical service organization (MSO) + home care + radiopharmaceuticals that "extends along the patient pathway into higher-value-add segments"; but it looks more like an "upgraded extension" of core distribution than an independent new engine capable of exploding on its own and recreating another CAH — and the credibility of this "baton pass" has already been discounted by one goodwill impairment.

  The second curve genuinely exists — it's not a slide deck. The proof is that it's already showing up in both revenue and profit:

  • Specialty/MSO (the clearest second curve). Management's FY2026 guidance points to specialty revenue exceeding $50 billion, about 16% three-year compound growth, with The Specialty Alliance already covering about 3,000 specialty physicians across 32 states, focused on the three high-value treatment areas of oncology, urology, and rheumatology. This line was built through a string of acquisitions: GI Alliance (about $2.8 billion, buying 73% initially), ION (about $1.1 billion), ADS (about $1.1 billion), and Solaris Health (about $1.9 billion, the country's largest urology MSO with 750+ physicians, 250+ practice locations, across 14 states).

  • Home care, radiopharmaceuticals/precision health, OptiFreight logistics. The report lists these as growth segments beyond the two traditional core segments, again with the logic of lengthening and thickening the chain along an existing hospital/patient network.

  This curve is a real "baton-taker" candidate, but by Baillie Gifford's standards its credibility needs a clear-eyed look, with three hard deductions:

  First, it is essentially an extension "fed by" core distribution cash flow, not a self-propelled new species. The report exposes its funding structure — heavy debt for acquisitions: total debt rose from $5.092 billion in FY2025 to $8.527 billion, and further to $8.916 billion by FY2026 Q3, used mainly for the GIA, ADS, and Solaris acquisitions. This is a classic roll-up path: building scale by continually buying physician networks, rather than an organic, self-replicating product/platform growing exponentially. The second curve Baillie Gifford favors is one that "grows naturally out of R&D or network effects"; CAH's is "bought" — the risk and quality profiles are worlds apart.

  Second, the "operating assumptions" behind the second curve have already been marked down once by reality. This is the most important honest flag: in FY2026 Q3 the company took a $184 million pre-tax goodwill impairment on the Navista & ION reporting unit, mainly due to a rise in the discount rate driven by a change in the risk profile of the business plan; after the impairment, that unit's carrying value is about $1.1 billion, of which $909 million is goodwill. In other words, at least one piece of the second curve the company is most bullish on has just had its long-term assumptions revised downward — showing that the "baton pass" isn't a sure thing, and real uncertainty remains around integration and returns.

  Third, is this a genuine baton pass, or just "moving the same pool of healthcare spending to a thicker-margin slice"? Specialty is indeed more profitable (buy-and-bill drugs carry high unit value), but it's still splitting existing U.S. healthcare spending rather than opening a new market; and all three giants are competing for the same pool of physician networks. This curve can improve CAH's profit mix, but it's hard for it to transform CAH into a high-growth company.

  Overall judgment: the second curve (specialty/MSO/home care/radiopharma) genuinely is ramping up in revenue and profit today, and it's a real bright spot relative to pure-distribution peers; but it is essentially a debt-funded roll-up "bought extension" rather than a self-generated flywheel, and the $184 million Navista & ION goodwill impairment has already discounted its operating assumptions. It qualifies as a real baton-pass candidate whose credibility has taken a hit; placed in the "bought extension" tier of 4, between ABB/AAPL's 5 and a far-out option's 3.

  Jun 10, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?5/10

  A

  Conclusion: its core competitive advantage is an operating-system moat built on "scale + regulatory licensing + warehousing/logistics and settlement infrastructure" (not brand or pricing power); over the next three to five years, this moat will most likely be "stable with slight improvement but not meaningfully widening" — the specialty/home-care extension adds increments, while thin margins and large-customer dependence in core distribution cap the upside.

  First, define what the moat actually is. The report judges that CAH's strongest asset isn't its brand, but scale, compliance, and infrastructure: it's one of the top three U.S. drug wholesalers, with the Big Three together accounting for more than 90% of pharmaceutical wholesale distribution; drug distribution requires DEA/state licensing, cold-chain and warehousing/logistics networks, inventory systems, settlement/recall/returns/traceability capability, and GPO/large-customer contracting capability — none of which a small player can quickly replicate. The report breaks the moat type down in detail: cost/scale advantage is moderate to strong, channel advantage is moderate to strong, licensing/regulatory barriers are moderate to strong, while brand is weak to moderate, network effects are weak, and switching costs are moderate but not absolute. In short: this is an "operating-system moat," not a "luxury-brand moat."

  Why "slight improvement over the next three to five years" — the sources of improvement are real:

  • Specialty/MSO/home-care extension is deepening its status as a "system node." The company is directing capital toward segments closer to physicians and patients — The Specialty Alliance already covers about 3,000 specialty physicians across 32 states, with specialty revenue guided to exceed $50 billion in FY2026. Bundling physician-practice management, buy-and-bill drugs, and home delivery into its own network raises customer embeddedness and switching costs — this is the direction in which the moat is widening.

  • The scale-economics moat in generic-drug purchasing is still being reinforced. CAH improves bargaining power and procurement efficiency through its Red Oak Sourcing purchasing joint venture with CVS, and the report notes this agreement runs through June 2029 — a classic "the bigger you are, the cheaper you can buy, the more competitive you get" scale flywheel.

  Why it also "won't widen meaningfully" — the boundaries are just as hard:

  1. Core distribution is inherently thin-margin and fiercely competitive. The company states plainly in its 10-K that drug distribution operates in a highly competitive environment, naming McKesson and Cencora as its primary national competitors. Three players splitting 90% of the market means all three are strong and none can easily pull ahead — price competition keeps a long-term lid on margins.

  2. Large customers can switch suppliers — the moat doesn't stop contract loss. The report's most persuasive counter-evidence is the OptumRx contract expiration — that customer once contributed 17% of FY2024 consolidated revenue and directly weighed on FY2025. If the moat were wide enough, a customer of that scale shouldn't be able to simply walk away.

  3. "High-growth blockbuster category" does not equal "captures high profit." GLP-1 sales boosted revenue but did not meaningfully contribute to segment profit — showing that even standing at the gateway to a hot category, CAH still lacks the pricing power to turn traffic into thick profit, which is exactly what a "narrow" moat looks like.

  4. The new moat hasn't been validated yet. The FY2026 Q3 $184 million Navista & ION goodwill impairment is a reminder that the "new stretch of moat" built from the specialty extension is still under construction, and not all of it may end up wide.

  5. Both up and down the value chain are stronger than it. Drugmakers sit above, and large customers/pharmacies/hospitals/payers sit below — the middleman's margin is naturally squeezed; the company also depends on the top five suppliers for 37% of FY2025 revenue (the largest supplier about 9%) and the two large GPO members together for 27% — bargaining power is squeezed from both ends.

  Overall judgment: this is a genuine, hard-to-breach "operating-system moat," sufficient to secure demand resilience and cash flow through the cycle; but its trajectory is "stable with a slight widening," not "rapid widening" — specialty/home care pushes the moat's edge outward a bit, while thin margins, intense competition, and large-customer dependence keep it firmly capped. By Baillie Gifford's yardstick, this is a "steady, narrow moat" — able to defend but not attack — which doesn't fit the growth-stock profile of "a moat that keeps meaningfully widening in the years ahead."

  Jun 10, 2026
• QIf its core business were disrupted, does it have the genes to reinvent itself? How does it handle mistakes and bad news?4/10

  A

  Conclusion: CAH's "self-reinvention genes" are incremental-improvement type, not disruptive-regeneration type — it can use acquisitions to upgrade itself from pure distribution to a "distribution + specialty platform," but it hasn't demonstrated a track record of striking out on its own with internal capability if its core business were genuinely disrupted; its attitude toward mistakes and bad news is relatively mature — it discloses proactively, takes impairments, and restates statements — but the very fact that it "discloses" also exposes that its controls and judgment have slipped before.

  First, address the implicit premise — "if the core business were disrupted, does it have the genes to reinvent itself."

  What CAH has demonstrated is a kind of "proactive extension rather than passive survival" reinvention: rather than waiting for distribution to be disrupted, it has already been shifting capital from core cash flow toward specialty, MSO, home care, radiopharma, and other higher-value-add segments — completing GI Alliance (about $2.8 billion, buying 73% initially), ION (about $1.1 billion), ADS (about $1.1 billion), and Urology America (about $400 million) in FY2025, and folding in Solaris Health (about $1.9 billion) in FY2026. This shows management has the drive to not "settle for being a thin-margin pass-through," and the direction is right. But it's important to be honest about the nature of this reinvention:

  • It is a "bought reinvention," not a "grown reinvention." The path is roll-up: building a new business by continually acquiring physician networks, rather than organically branching out through in-house R&D or network effects. The "self-reinvention genes" Baillie Gifford truly values are a company's ability to incubate an entirely new growth pole using internal capability when it itself is disrupted by technology or business-model shifts (like Amazon growing AWS out of e-commerce); CAH's reinvention depends heavily on external assets and continued borrowing (total debt rose to $8.527 billion in FY2025 and $8.916 billion by FY2026 Q3, used mainly for these acquisitions).

  • The real disruption threat is precisely the direction this reinvention is trying to dodge. The report notes that CAH's disruption doesn't come from "drugs no longer being needed," but from shifts in value allocation: PBMs/large health insurers building in-house distribution capability, limited-distribution models, payer price pressure, and vertical integration within the specialty track. Ironically, CAH's own vertical push into specialty is itself competing for the same territory as these potential disruptors — whether it can secure its position before being disrupted is, for now, an open question.

  • And this reinvention path hasn't yet been proven successful. The piece it's most bullish on has already been slapped down by reality: FY2026 Q3 saw a $184 million pre-tax goodwill impairment on Navista & ION, mainly due to a change in the business plan's risk profile and a rise in the discount rate. The reinvention move has been made, but whether it will actually pay off remains a question mark.

  Now to "how does it handle mistakes and bad news" — CAH's performance here is relatively commendable, but mixed:

  The commendable side: transparent, willing to admit errors, willing to take impairments. In October 2024 the company proactively disclosed a "long-standing" accounting error (involving revenue recognition on third-party payer contracts within the at-Home Solutions segment) and restated prior-period statements; in FY2026 Q3 it also didn't paper over the missteps in its specialty acquisitions, taking a direct $184 million impairment on Navista & ION. The report also notes the company adopted a Dodd-Frank/SEC/NYSE-compliant clawback policy in November 2023. This attitude of "disclosing bad news as-is, taking impairments when warranted" is far healthier than companies that cover up problems, and is exactly the kind of "honesty about mistakes" Baillie Gifford values.

  The side to watch: "willingness to disclose" precisely shows the problems really happened, more than once. The report lists these two items together as deductions from confidence in "noise-free reporting" — a long-standing revenue-recognition error (the company itself acknowledges that a one-time current-period correction would have had a material effect on FY2024) plus a specialty-acquisition impairment — compounded further by opioid-litigation liabilities still carrying a cumulative accrual of $4.9 billion at the end of FY2025, with $798 million paid in cash that year. Candor is a virtue, but the content of that candor is "we've made judgment/control mistakes before" — which is itself a risk signal.

  Overall judgment (Baillie Gifford lens): CAH has the benign genes of "proactive extension, honest error admission," which keeps it from sitting idle amid change; but it lacks a hard track record of "striking out on its own with internal capability when the core is disrupted," and its reinvention is bought and not yet proven successful. Its maturity in handling bad news deserves credit, but it can't fully offset the Baillie Gifford-style shortfall of "self-reinvention capability that hasn't been tested by a true near-death crisis" — this is a good business that will respond soundly to change, not a great business that can rise from the ashes of disruption.

  Jun 10, 2026
• QDoes management (especially the founder) have a long-term view, and are their interests deeply tied to the company? Are they willing to sacrifice near-term profit for the next five to ten years?5/10

  A

  Conclusion: management is "professional executives" rather than founders — interest alignment relies on institutionalized stock-ownership requirements rather than natural equity ownership, and their long-term view and interest alignment are "moderately above average, adequate but not exceptional"; they are willing to sacrifice current reported results for the longer-term specialty transformation (debt-funded M&A, absorbing impairments), but that "sacrifice" also carries the risk of overpaying that comes with a roll-up.

  First, lay out the facts about "alignment" — this company has no founder, so the "founder-style deep alignment" Baillie Gifford values most is structurally absent; all that's left to assess is how well institutional mechanisms fill the gap:

  • The CEO is a professional executive with a moderate tenure. Jason Hollar has served as CEO since September 2022, and as of the 2025 proxy statement had been with the company for about 5 years — he was hired to execute a transformation, not a founder with his life's fortune riding on the company.

  • A mandatory stock-ownership requirement pins his interests to the share price. The report notes the company has a fairly strict executive stock-ownership threshold: the CEO must hold shares worth 6x salary, and must retain 100% of net after-tax shares until that requirement is met; as of the 2025 proxy statement, Hollar's actual stockholding value was about $27.35 million, equal to 18.2x base salary, well above target. This is institutionalized alignment — stronger than at many large companies where ownership requirements are merely symbolic — but it's "alignment forced by rules," not a founder's natural "I am the company" alignment; it's one notch weaker in kind.

  • Incentive metrics don't just chase EPS, and discipline is relatively restrained. FY2025 cash incentives incorporate adjusted operating earnings, adjusted free cash flow, and strategic and culture goals; the FY2025-2027 PSUs incorporate adjusted EPS CAGR, average dividend yield, and adjusted free cash flow, modified by relative TSR; the company's equity dilution rate (annual equity run rate) is only 0.39%, and it no longer grants option-type incentives — this design puts cash flow and shareholder returns into the scorecard, which is healthier than an "EPS-only" approach. The report characterizes this as moderately-above-average honesty and moderate capital-allocation ability.

  Now to the implicit premise — "are they willing to sacrifice near-term profit for the next five to ten years" — the answer is "yes, and they're actually doing it, but the manner carries risk":

  The evidence of willingness to sacrifice the present is concrete. Management is using core distribution cash flow and substantial borrowing to buy specialty assets whose payoff won't show up for years: total debt rose from $5.092 billion in FY2025 to $8.527 billion, and to $8.916 billion by FY2026 Q3, used mainly for the GIA, ADS, and Solaris acquisitions; and in FY2026 Q3 it took the $184 million goodwill impairment on Navista & ION without hiding it, owning the number directly. Absorbing an impairment that depresses current GAAP profit while betting on longer-term structural improvement is itself a "sacrificing the present for the future" posture. As a result, the company has also confidently and repeatedly raised its FY2026 guidance — non-GAAP diluted EPS guidance has been raised and narrowed to $10.70–10.80, implying about 30%–31% growth.

  But the quality of this "sacrifice" needs a discount, for three reasons that must be honestly flagged:

  1. The original sin of a roll-up is that it fears overpaying and integration failure most of all. The report points out that this path of extending from distribution into specialty inherently carries roll-up characteristics, and the Navista & ION impairment has already proven that the long-term assumptions behind at least some acquired assets were marked down — "willingness to sacrifice the present" isn't necessarily good for shareholders if what it buys turns out to be overpriced.

  2. Buyback discipline has shown a recent flaw. The report notes that the FY2026 Q3 ASR program received its initial delivery at a $215.42 reference price, with a final closing VWAP of $209.55 — a level already near or above the midpoint of the report's estimate of "fair value," showing that management keeps buying back even at elevated levels, not always "only buying when cheap." This is exactly why the report "retains some skepticism."

  3. There's no founder-style long-termism as a natural baseline. Mandatory stock ownership can align interests, but it can't substitute for a founder's "day-in, day-out, reputation and net worth all on the line" long-term view. The CEO's tenure is about 5 years, the transformation's payoff won't be clear for 5-10 years, and whether the same person will still be at the helm by then is itself a variable.

  Overall judgment (Baillie Gifford lens): management has a clear direction, a restrained incentive design, and is willing to absorb near-term reported-earnings pressure for the longer-term transformation, with interest alignment adequately handled through institutional means — this is a "qualified, worth a degree of trust" management team; but it lacks founder-style deep alignment and long-term view, and its capital allocation carries the flaws of a leveraged, roll-up-style high-price M&A strategy and high-level buybacks. Measured against Baillie Gifford's high bar of "founder long-termism," this item is moderately above average — adequate but not outstanding, and it doesn't fit the growth-stock profile of "management itself being the moat."

  Jun 10, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable, without relying on harm to society or regulatory arbitrage?6/10

  A

  Conclusion: if CAH disappeared tomorrow, the entire U.S. healthcare system would "miss it immediately and severely" — but what would be missed is the "distribution infrastructure" position it occupies, not the company itself (the position is indispensable, the company is replaceable); its growth model is broadly legal and compliant, not reliant on harming society, but it sits in a high-pressure zone of opioid-litigation aftermath and antitrust/drug-pricing regulation, so "social and regulatory sustainability" is a real variable that needs continuous monitoring.

  First, address the implicit premise of "indispensability" — this splits into two layers, and the conclusion is "the position is indispensable, the individual company is replaceable":

  This slot is highly indispensable. CAH is one of the top three U.S. drug wholesalers; more than 90% of prescription drugs are distributed through wholesalers, and the Big Three together account for more than 90% of pharmaceutical wholesale distribution. Its network is embedded in the daily operation of hospital replenishment, retail/independent pharmacies, outpatient surgery centers, clinics, home care, and even patient-to-home delivery. The report notes its resilience comes from "position and scale" — during an economic downturn, hospitals, pharmacies, and patients still need drugs — so if it really disappeared, there would be a genuine near-term supply-chain gap, and customers would miss it badly. This is a "utility-style" indispensability.

  But the company itself is replaceable. This is the key point that must be honestly flagged: what customers can't do without is "someone doing the distribution," not "it has to be CAH." The hardest counter-evidence is the OptumRx contract expiration — that customer once contributed 17% of FY2024 consolidated revenue and simply walked away, weighing on FY2025. If CAH were truly irreplaceable, a customer of that scale wouldn't easily switch to McKesson or Cencora. The report also explicitly names those two as interchangeable national competitors. In other words, if any one of the Big Three disappeared, the other two would quickly fill the gap — the healthcare system would wobble but not collapse. The full "customers would be devastated tomorrow and no one could replace it" indispensability Baillie Gifford is really looking for — CAH only satisfies the first half.

  Now the implicit premise of "is growth sustainable, without relying on harm to society or regulation" — broadly compliant, but sitting in a high-pressure regulatory zone:

  The main growth model is legal, compliant, and socially positive in value. Efficiently and safely moving drugs from manufacturers to patients is itself a non-discretionary need of the healthcare system; the specialty/home-care extension (The Specialty Alliance covering about 3,000 specialty physicians across 32 states) is also improving patients' local access to specialty care. This isn't a business built on harming users or exploiting regulatory loopholes.

  But there are three hard "social/regulatory sustainability" constraints to watch:

  1. The opioid litigation is a social cost hanging over its head. The report notes cumulative accrued opioid-related liabilities of $4.9 billion at the end of FY2025, with $798 million paid in cash that year. This is a live example of "a distributor's growth once caused harm to society to some degree, and it is paying a long-term price for it" — the broad framework is now settled, but it reminds investors that distribution-volume expansion hasn't come without a legal and social backlash tail.

  2. Vertical integration into physician practices is drawing antitrust and conflict-of-interest scrutiny. The Big Three have collectively spent over $16 billion acquiring MSOs in recent years, extending their reach into oncology and other specialty practices, which has already drawn regulatory scrutiny of their expansion into cancer care. CAH's second curve sits right under this regulatory spotlight — whether "doing distribution and physician-practice management at the same time" constitutes a conflict of interest is a real question mark for sustainability.

  3. Drug pricing, reimbursement, and licensing policy directly constrain the profit model. The report lists changes in Medicare/Medicaid reimbursement, payer price pressure, drug-pricing policy, state/federal licensing, and privacy/data regulation as risk factors — these are structural, policy-driven, and would directly compress an already thin margin if tightened.

  Overall judgment (Baillie Gifford lens): CAH occupies an "immediately missed if it disappeared tomorrow" indispensable slot, and its demand stickiness and social necessity are real — that's the basis of its defensive-stock credentials; but the company itself is replaceable by peers, and its growth sits within a triple high-pressure zone of opioid-litigation aftermath, antitrust, and drug-pricing regulation. Measured against Baillie Gifford's yardstick of "indispensable and cleanly, sustainably growing," it clears the "customers would miss it" bar, but gets stuck on "irreplaceable" and "zero regulatory/social tail risk" — this is an important, compliant business, not a great one that "no one can replace, with growth free of social and regulatory risk."

  Jun 10, 2026
• QWhat are this business's unit economics (gross margin, incremental returns) like? Do they get better or worse as it scales up? Where does the money it earns go?4/10

  A

  Conclusion: unit economics fit the classic distribution model of "extremely thin gross margin plus extremely high turnover, earning money from working capital rather than high per-unit profit" — scaling up dilutes costs and improves things slightly (specialty/private-label are the few thicker-margin pockets), but nowhere near the level of "high incremental returns"; the money it earns goes mainly to dividends/buybacks and specialty acquisitions (debt-funded). This is the single biggest reason CAH doesn't earn a place in the Baillie Gifford growth story.

  First, look at how thin the unit economics really are — using real FY2025 numbers:

  Gross margin is thin down to the penny. FY2025 total revenue was $222.6 billion, with GAAP operating profit of only about $2.275 billion and non-GAAP operating profit of about $2.786 billion — an operating margin of only about 1% (GAAP) to 1.25% (non-GAAP). The comparison between the two segments makes the point even clearer: Pharmaceutical and Specialty Solutions revenue was $204.6 billion with segment profit of $2.258 billion (margin about 1.1%); Global Medical Products and Distribution revenue was $12.6 billion with segment profit of only $135 million (margin about 1.1%). Skimming just over $2 billion in profit off a $200 billion-plus revenue base — that is the true face of a distribution business.

  Money is made from turnover and working capital, not per-unit profit. The report exposes the model's true nature: CAH isn't a capital-intensive manufacturer — it's a distributor with enormous working capital and razor-thin gross margin — inventory of $16.831 billion, receivables of $13.242 billion, and payables of $34.713 billion at the end of FY2025; capex of only $547 million (negligible against $200 billion-plus revenue). Note that payables far exceed inventory plus receivables, meaning it uses upstream payment terms to fund downstream operations and earns money through high-speed turnover and settlement management — which is also why a blockbuster category like GLP-1 drives revenue without contributing segment profit: it passes through the ticket, and earns the toll.

  Now, "does unit economics get better or worse as the company scales" — somewhat better, but with a very low ceiling:

  The improvement is real, but limited. Greater scale means stronger purchasing leverage (the Red Oak Sourcing joint purchasing platform with CVS runs through June 2029) and more diluted fixed warehousing/logistics costs; private-label Cardinal Health-branded medical products and specialty drugs are typically the thicker-margin pockets. FY2025 the company did grow non-GAAP operating profit +15% and GMPD segment profit +47%, showing the structural optimization is working.

  But incremental returns are far from excellent, and are distorted by accounting. The report specifically flags that CAH's return on capital "headline metrics are distorted by negative working capital and negative net assets" — the company has had negative shareholders' equity of about -$2.634 billion in FY2025 and about -$2.672 billion in FY2026 Q3 (driven by a large amount of treasury stock/buybacks), meaning metrics like ROE have essentially no reference value. Strip out these distortions, and a business with an operating margin just over 1% inherently generates mediocre marginal returns on new capital — this is exactly the "incremental returns" dimension Baillie Gifford cares about most, and CAH can't score high on it.

  Finally, "where does the money it earns go" — three destinations, of mixed quality:

  1. Dividends and buybacks (long disciplined). FY2023/24/25 buybacks were about $2 billion / $750 million / $765 million; dividends were about $525 million / $499 million / $494 million; diluted share count fell from 294 million in FY2021 to 242 million in FY2025 and further to 238 million in the first nine months of FY2026. The large drop in share count genuinely improved per-share value — but the report notes recent buyback prices (FY2026 Q3 ASR reference price $215.42, VWAP $209.55) are no longer cheap, so the returns aren't as obvious anymore.

  2. Specialty/MSO acquisitions (betting on the future, but debt-funded and already impaired). A large amount of cash has gone into GI Alliance, ION, ADS, and Solaris acquisitions, pushing total debt to $8.916 billion by FY2026 Q3; and Navista & ION have already been impaired by $184 million, showing that the return on this "reinvestment" carries real uncertainty.

  3. Passive cash outflows (non-growth-related). FY2025 opioid cash payments were $798 million — this money neither creates growth nor rewards shareholders; it's payment for a legacy burden.

  Overall judgment (Baillie Gifford lens): CAH's unit economics are "an extremely thin-margin model that survives on turnover and working capital" — scale brings modest improvement but structurally lacks high incremental returns; the money earned goes mainly to buybacks/dividends (disciplined but no longer cheap recently) and specialty M&A (betting on the future, but debt-funded and already impaired). Measured against Baillie Gifford's yardstick of "high margin, high incremental returns, the bigger it gets the more it earns," this is exactly CAH's weakest link — it's a stable cash-turnover machine, not a compounding machine whose unit economics keep improving as it grows.

  Jun 10, 2026
• QFor it to rise five-fold in ten years, what conditions would all need to hold simultaneously? Are those conditions realistic? What expectations does today's share price already imply?2/10

  A

  Conclusion: the conditions for CAH to rise five-fold in ten years are almost impossible to all hold at once — this would require a thin-margin oligopoly distributor with an operating margin just over 1% and low-single-digit organic growth to simultaneously achieve "a hugely successful specialty transformation, a structural leap in margins, and no valuation-multiple compression," which conflicts with the essence of its business; and today's share price of about $216 implies not "cheap because bad news is fully priced in," but rather a not-low expectation that "a neutral-to-optimistic scenario has already been largely priced in" — the margin of safety is insufficient.

  First, the implicit premise — "what conditions must all hold simultaneously for a ten-year five-fold return" — breaks down into a multiplication problem, and every term is tight:

  A five-fold return is roughly 17.5% annualized over ten years. For a steady distributor, this requires the following to be true simultaneously:

  1. Profit (not revenue) growing several-fold over ten years. Even doubling revenue is hard (see the corresponding Q&A), let alone a five-fold increase in profit. CAH's operating margin is only about 1% (FY2025 GAAP operating profit of $2.275 billion on revenue of $222.6 billion) — growing profit five-fold from this thin-margin business would almost require specialty to lift the overall margin by an order of magnitude — a structural leap, not an incremental extension.

  2. The specialty/MSO transformation not only succeeding, but delivering high-quality profit well above the cost of capital. The report lists this as one of the most fragile assumptions, and reality has already taken a bite out of it: FY2026 Q3 saw a $184 million goodwill impairment on Navista & ION. This line would need to keep firing on all cylinders for ten years with no major stumbles for a five-fold return to even be on the table — the odds aren't high.

  3. The core distribution customer base staying free of major trouble for ten years. The report documents the OptumRx contract expiration — once 17% of FY2024 revenue — directly weighing on FY2025. A five-fold story can't survive one or two more losses of that magnitude over ten years.

  4. The valuation multiple not compressing — ideally expanding. This is the most fatal condition. CAH's current trailing P/E is already about 31.9x, significantly above McKesson's roughly 22.1x and Cencora's roughly 21.1x. A thin-margin distributor trading above 30x is already on the high side historically; for a five-fold return, the multiple can't even revert toward peer levels — and CAH is already up about 74% over the past year, far outpacing the broad market's 13.9% and the healthcare sector's -19.7%, meaning the "valuation re-rating" card has very likely already been played, if not overdrawn.

  Multiplying these four together: low-single-digit organic growth × a specialty transformation that must succeed flawlessly × ten years without a major customer blowup × no valuation compression. If any one term slips, the five-fold outcome collapses — and the odds of all of them holding at once are extremely low. This is precisely the "ten-year five-fold" yardstick that CAH is almost certain to fail.

  Now the implicit premise of "what expectations does today's price imply" — using the report's valuation anchors plus the current price:

  Against the $200.68 snapshot with a market cap of about $47.36 billion, the report's three-scenario owner-earnings discounting gives: conservative about $140/share, neutral about $201/share, optimistic about $297/share, and explicitly states "the current price roughly corresponds to the upper end of the neutral scenario." In other words, the report already judged that the market had paid a not-low price for "specialty expansion succeeding plus cash-flow normalization," with insufficient margin of safety.

  And today the share price has already risen to about $216.26, with a market cap of about $50.65 billion (June 10, 2026), about 8% higher than the report's snapshot, meaning the market is now pricing in even fuller expectations than at the time of the report's assessment — already past the neutral-scenario midpoint of $201/share and drifting toward the optimistic range. Even with fundamentals cooperating (FY2026 non-GAAP EPS guidance raised to $10.70–10.80, about +30%–31%, specialty revenue guidance above $50 billion), the current price looks more like "good news paid for in advance" than "a cheap bargain." The report's ideal buy range is $145–170, and today's price is still a good distance from that.

  Overall judgment (Baillie Gifford lens): a ten-year five-fold return requires four tight conditions to hold simultaneously, and they conflict with CAH's fundamental nature of "thin margin, low growth, scale bought through M&A" — the realistic probability is extremely low; today's price of about $216 implies expectations that are "neutral-to-optimistic and already priced in, even drifting toward optimistic," rather than a margin of safety built on bad news being fully priced in. By Baillie Gifford's standard, this isn't a "high-odds, cheap price, large upside" growth opportunity — it's a steady stock whose story has basically already been told by the market, and told at a fairly high price — which is also the fundamental reason the report lands on "Watch, insufficient margin of safety."

  Jun 10, 2026
• QWhy hasn't the market recognized all this yet? Does it not understand, does it look down on the company, or does it lack foresight? What would become the "narrative inflection point"?3/10

  A

  Conclusion: for CAH, the question of "why hasn't the market noticed" actually needs to be flipped around — the market hasn't failed to notice; it has already fully noticed, and even re-rated the stock to reflect it. The share price is up about 74% over the past year, with a valuation now above its peers, showing the narrative inflection point (specialty transformation plus cash-flow recovery) has already happened and been priced in; the real perception gap today is more likely on the "has it gotten too optimistic" side, rather than "an undiscovered bargain."

  First, correct the premise of the question. Baillie Gifford's "doesn't understand/looks down on/lacks foresight" framing usually assumes there's an undervalued opportunity the market hasn't yet recognized. But CAH's facts run the other way: over the past year CAH's share price is up about 74%, far outpacing the broad market's 13.9% and the healthcare sector's -19.7%, with a 52-week range of about $114.60–213.90, and a closing high of about $229 in March 2026. The report's snapshot price of $200.68 already corresponded to a trailing P/E of about 31.9x, above McKesson's roughly 22.1x and Cencora's roughly 21.1x, and today it has risen further to about $216. A stock the market "looks down on and doesn't understand" wouldn't get bid up to be the most expensive in the whole industry — so the correct read is: the market has long since seen it, and has awarded it a premium.

  So what has the market seen, and why is it willing to pay a premium — the narrative inflection point has, in fact, already happened:

  • The reversal from "hurt by the OptumRx cutback" to "specialty ramping, profit growing against the grain." The market has seen that FY2025 GAAP operating profit still rose 83% and non-GAAP profit rose 15% even as revenue fell 2% due to the OptumRx expiration, proving "you can still fatten profit even after losing a large customer" — that was the first inflection point priced in.

  • The specialty transformation turning from "story" into "numbers." FY2026 nine-month revenue +17%, the Pharma and Specialty segment +18%, with management repeatedly raising non-GAAP EPS guidance to $10.70–10.80 (about +30%–31%) and specialty revenue guidance above $50 billion, about 16% three-year compound growth. The market is buying the certainty of this specialty curve delivering.

  • Shareholder-return discipline. Share count has fallen steadily from 294 million in FY2021 to 238 million in the first nine months of FY2026, and the market has rewarded the resulting per-share value improvement.

  So from a Baillie Gifford lens, CAH's real "perception gap" today isn't on the undervalued side, but possibly on the over-optimistic side — what the market may not be "seeing" is that this remains a thin-margin distributor with an operating margin just over 1% (FY2025 GAAP operating profit of $2.275 billion on revenue of $222.6 billion), that the specialty transformation is a debt-funded roll-up (total debt rose to $8.916 billion by FY2026 Q3), and that it has already taken a $184 million Navista & ION goodwill impairment. This lines up with the report's own conclusion: the current price already sits at the upper end of the neutral scenario, with an insufficient margin of safety.

  Now the implicit premise of "what would become the narrative inflection point" — since the upside inflection has largely already played out, what's worth watching now is the downside inflection that could reverse the current optimistic narrative, plus the few upside catalysts that could still extend it:

  What would shatter the current optimistic narrative (downside inflections, need more vigilance):

  1. Another major specialty goodwill impairment. Following Navista & ION, another significant goodwill impairment would directly disprove the core assumption of "high-quality transformation" — the report lists this as one of the top reassessment triggers.
  2. Losing another OptumRx-scale large customer. The report is explicit that losing another customer at close to OptumRx's scale (about 17%) would immediately flip the narrative.
  3. Normalized free cash flow staying clearly below $1.8 billion for two straight years, or net debt/EBITDA continuing to climb. This would puncture the "cash-flow recovery plus manageable leverage" story.
  4. Drug-pricing/reimbursement/antitrust policy dealing a structural blow to the profit model. Especially since vertical integration into physician practices is already drawing regulatory scrutiny of the Big Three's expansion into cancer care.
  5. Valuation reverting toward peers. Currently above 30x versus MCK/COR's low 20s — if market sentiment cools and the multiple compresses, the share price would come under pressure even with unchanged fundamentals.

  What could extend the optimistic narrative (upside inflections, though much of the room has already been used up): specialty margins proving structurally higher than pure distribution, M&A integration exceeding expectations, and opioid cash outflows declining year after year to free up more distributable cash — these would support the valuation, but since the stock has already rallied hard, making new highs would require beating expectations, not merely meeting them.

  Overall judgment (Baillie Gifford lens): CAH isn't "an undervalued opportunity the market hasn't yet noticed" — it's a name whose "narrative inflection point has already happened, and the market has already re-rated it, possibly to the high side." The real perception gap is more likely on the over-optimistic side. The key inflection ahead isn't "when will the market discover it's good," but "will a specialty impairment/large-customer loss/valuation reversion puncture the already-fully-told optimistic story." By Baillie Gifford's yardstick, this is the mirror image of "lacking foresight": the market sees it very clearly, and has paid up for it — leaving latecomers with little margin of safety, fully consistent with the report's own conclusion of "Watch, insufficient margin of safety."

  Jun 10, 2026